Literature DB >> 8918517

Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs.

J F Bugge1.   

Abstract

A 40-year-old woman with transplanted lungs developed life threatening hyperkalaemia (6.8 mmol L-1) during high dose treatment with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia. Trimethoprim has an amiloride-like effect on the distal nephron and may thus induce hyperkalaemia, particularly if other contributing factors coexist. The present patient was also treated with the angiotensin-converting enzyme (ACE) inhibitor enalapril, and the combination of ACE-inhibition and potassium-sparing diuretics is known to induce hyperkalaemia. Hyperkalaemia was probably induced by the combination of ACE-inhibitor and trimethoprim, and this combination may be as dangerous as the combination of ACE-inhibitors with other potassium-sparing diuretics.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8918517     DOI: 10.1046/j.1365-2796.1996.43869000.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  5 in total

1.  Trimethoprim-sulfamethoxazole associated with hyperkalemia.

Authors:  M A Marinella
Journal:  West J Med       Date:  1997-11

Review 2.  Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management.

Authors:  M A Perazella
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

3.  Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study.

Authors:  Michael Fralick; Erin M Macdonald; Tara Gomes; Tony Antoniou; Simon Hollands; Muhammad M Mamdani; David N Juurlink
Journal:  BMJ       Date:  2014-10-30

Review 4.  Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients.

Authors:  John G Rizk; Jose G Lazo; David Quan; Steven Gabardi; Youssef Rizk; Elani Streja; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Rev Endocr Metab Disord       Date:  2021-07-22       Impact factor: 6.514

5.  Trimethoprim-sulfamethoxazole-induced hyperkalemia in a patient with normal renal function.

Authors:  L Connor Nickels; Christine Jones; Latha Ganti Stead
Journal:  Case Rep Emerg Med       Date:  2012-12-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.